Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Valganciclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.73 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.38 |
| ▸ | PNP known ✓ | P00491 | 1/20 | 0.35 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.35 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HPRT1 | P00492 | 11/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Valganciclovir SCHEMBL28997 | 0.99 | PDE3A (0.74) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL28996 | 0.99 | PDE3A (0.74) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL1652839 | 0.97 | PDE3A (0.71) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL3237941 | 0.96 | PDE3A (0.70) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL6479139 | 0.92 | PDE3A (0.68) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL15251689 | 0.92 | PDE3A (0.83) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL1120942 | 0.92 | PDE3A (0.85) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL3134972 | 0.90 | PDE3A (0.62) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL336814 | 0.88 | PDE3A (0.78) | PDE3AHBBMAPK1MEN1KMT2A | |
| Valganciclovir SCHEMBL18837501 | 0.87 | PDE3A (0.77) | PDE3AHBBMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 936 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925079-B | Amplified preparation method of valganciclovir hydrochloride | 湖北天义药业有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-118698475-A | Valganciclovir hydrochloride intermediate preparation device and method | 湖北葛店人福药业有限责任公司 | 2024-09-27 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-113880838-B | Method for synthesizing valganciclovir hydrochloride by micro-channel reactor | 仁合益康集团有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-11912667-B2 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | EMERGENT BIODEFENSE OPERATIONS LANSING LLC (US) | 2024-02-27 | — | — | US | claimed |
| CN-220514447-U | Valganciclovir Wei Lixin hydrochloride device | 宜昌天仁药业有限责任公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117567470-A | Method for removing impurity palladium ions in valganciclovir hydrochloride | 黄冈人福药业有限责任公司 | 2024-02-20 | — | — | CN | claimed |
| CN-220159930-U | Hydrogenation reaction device for producing valganciclovir hydrochloride | 湖北保乐生物医药科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-115569113-B | Valganciclovir hydrochloride oral solution | 江苏汉晨药业有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116925079-A | Amplified preparation method of valganciclovir hydrochloride | 湖北天义药业有限公司 | 2023-10-24 | — | — | CN | claimed |
| US-20080146591-A1 | Contains non-hygroscopic organic acid as stabilizer; for oral administration, after being constituted in water | BACHYNSKY MARIA OKSANA | 2008-06-19 | — | — | US | claimed |
| WO-2008071573-A2 | POWDER FORMULATION FOR VALGANCICLOVIR | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-19 | — | — | WO | claimed |
| US-20070292499-A1 | Processes for the Preparation of Solid Dosage Forms of Amorphous Valganciclovir Hydrochloride | RANBAXY LABORATORIES LIMITED (IN) | 2007-12-20 | — | — | US | claimed |
| US-20070129385-A1 | Amorphous valganciclovir hydrochloride | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | US | claimed |
| EP-1725217-A1 | PROCESSES FOR THE PREPARATION OF SOLID DOSAGE FORMS OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE | RANBAXY LABORATORIES, LTD. (IN) | 2006-11-29 | — | — | EP | claimed |
| CN-1860120-A | Amorphous valganciclovir hydrochloride | RANBAXY LAB LTD (IN) | 2006-11-08 | — | — | CN | claimed |
| EP-1660499-A1 | AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE | Ranbaxy Laboratories Limited (IN) | 2006-05-31 | — | — | EP | claimed |
| WO-2005087198-A1 | PROCESSES FOR THE PREPARATION OF SOLID DOSAGE FORMS OF AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2005-09-22 | — | — | WO | claimed |
| WO-2005021549-A1 | AMORPHOUS VALGANCICLOVIR HYDROCHLORIDE | RANBAXY LABORATORIES LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-20050053653-A1 | delivering hydrobhobic drug containing meglumine as solubilizing agent; controlled release | SUPERNUS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912667-B2 | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof | PHOSPHO1, PPIP5K2, FASN | PDE3A 1710/4885BCHE 878/4885PNP 17/4885 |
| US-20070129385-A1 | Amorphous valganciclovir hydrochloride | ZC3HAV1, ZC3HAV1L, SEPTIN9 | PDE3A 2005/4885BCHE 1839/4885PNP 785/4885 |
| US-20080146591-A1 | Contains non-hygroscopic organic acid as stabilizer; for oral administration, after being constituted in water | OTC, RPL35, RPL26 | PDE3A 4698/4885BCHE 4057/4885PNP 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.